Automatic implantable cardioverter defibrillator: when not to implant

Area of Science:

• Cardiology
• Geriatrics
• Medical Devices

Background:

• The implantable cardioverter-defibrillator (ICD) is a primary therapy for preventing sudden cardiac death (SCD) in heart failure with reduced ejection fraction (HFrEF).
• Current ICD guidelines rely on trials from 15-20 years ago, with limited data on older adults (>75 years) and those with comorbidities.
• Evidence suggests reduced ICD efficacy with increasing age.

Purpose of the Study:

• To evaluate the efficacy of prophylactic ICDs in elderly patients with HFrEF.
• To investigate the impact of geriatric syndromes, particularly frailty, on ICD benefit in this population.
• To determine if frailty assessment can refine patient selection for ICD implantation.

Main Methods:

• Review of existing literature on ICD use in elderly patients with HFrEF.
• Analysis of age-dependent efficacy and the influence of comorbidities and geriatric syndromes.
• Exploration of frailty assessment tools and their predictive value for ICD benefit.

Main Results:

• Older age is associated with decreased ICD efficacy in primary SCD prevention.
• Geriatric syndromes, especially frailty, significantly impact health status and potentially alter ICD benefit.
• Frailty assessment may identify elderly patients unlikely to benefit from ICDs.

Conclusions:

• Current ICD indications may not be optimal for the aging population with HFrEF.
• Incorporating frailty assessment into clinical decision-making can help personalize ICD therapy for older adults.
• Further research is needed to validate frailty-based criteria for ICD implantation in the elderly.